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ABSTRACT
Because few patients failing autologous transplantation for Hodgkin’s disease survive long-term, we explored
reduced-intensity allografts using BEAM conditioning and early withdrawal of immunosuppression as an alternative
to palliative chemotherapy. Ten patients with Hodgkin’s disease underwent an allograft, receiving either matched
sibling peripheral blood stem cells (5), partially matched sibling bone marrow (1), or matched unrelated bone marrow
(4). Graft-versus-host disease (GVHD) prophylaxis was mini-methotrexate and FK-506 with weaning at day 60. The
median age of patients was 35 years (range: 21 to 49 years). The median time from initial diagnosis was 73 months
(range: 12 to 172 months) and from autograft was 49 months (range: 5 to 143 months). One patient was in CR, 5
patients were in partial remission, 3 were in relapse, and 1 patient had primary refractory disease. All patients’
transplants engrafted rapidly, and the 100-day mortality was 0. Two patients developed acute GVHD. Five of the 9
patients beyond 100 days have developed mild chronic GVHD, of which 1 case was progressive and required systemic
therapy. All 10 responded: 8 complete responses and 2 partial remissions. Three patients have relapsed (at 2, 6, and
8 months, respectively), 1 has died at 4 months. At a mean of 12 months (range: 1 to 21 months) after allograft, 9 of
10 patients are alive, with 7 in continuous remission. BEAM allogeneic transplantation with early reduction in
immunosuppression is safe (no treatment-related deaths) and effective in advanced Hodgkin’s disease where au-
tografts have failed. A graft versus lymphoma effect appears to be a significant contributing factor in responding
patients.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
During the past several decades, standard therapies for the
management of advanced Hodgkin’s disease (HD) have im-
proved, producing both higher complete remission (CR) rates
and event-free survival [1-4]. Despite this, approximately 30%
to 40% of advanced-stage HD provides ongoing challenges in
management, relapsing after standard adriamycin-containing
chemotherapy regimens [5].
Autologous transplantation is effective for many who re-
lapse, although for primary progressive HD, the progression-
free survival rate recently reported by the American Blood and
Marrow Transplant Registry was 38% at 3 years [6] and the
disease-free survival rate reported by the European Bone Mar-
row Transplant Registry was 32% at 5 years[7]. Similarly, for
relapsed patients resistant to conventional salvage chemother-
apy, the long-term survival rate after autografting was 10% to
31% [6,8,9]. This shows that many patients fail autologous
transplantation, and these patients have very limited therapeutic
options and a poor outlook.
Starting in 1985, allogeneic transplantation has been con-
sidered as an alternative option for cure in relapsed/refractory
HD [10]. Whereas previous studies have indicated an unaccept-
ably high transplant-related mortality, allogeneic transplanta-
tion has been found to be effective in a subgroup of patients with
HD who fail standard therapy, with 15% to 22% achieving
long-term disease-free survival [10-13]. Allogeneic bone marrow
or peripheral blood stem cell transplantation has various theo-
retical advantages. These include graft-versus-lymphoma
(GVL) effects by the donor lymphocytes and avoidance of the
risk of re-infusion of malignant cells, which may occur with
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autografting. Reports have indicated that withdrawal of immu-
nosuppresion with or without donor lymphocyte infusion (DLI)
can result in favorable disease response in patients who relapse
from other lymphoid malignancies after allogeneic transplanta-
tion [14-17].
Supportive of a GVL effect, the use of HLA-matched sib-
ling marrow transplantation in HD results in a lower relapse rate
compared with autografting [12], with some patients displaying
prolonged disease-free survival [13]. Discouragingly, treatment-
related mortality of up to 75% was reported [10-13] in these ﬁrst
series of HD allografts. Regimen-related pulmonary toxicity was
very common. Radiotherapy and/or busulfan were used in many
of the myeloablative regimens.
However, BEAM conditioning is established as a safe and
effective conditioning regimen for autografting in HD, includ-
ing patients failing to respond to the lower-dose “mini-BEAM”
[18], and has been recently used in allogeneic transplantation for
lymphoid malignancies [19,20]. It supports engraftment and is a
tolerable preparative regimen [21].
There appear to be few encouraging other options for
patients with HD relapsing after autologous transplantation.
Some centers have reported some early encouraging results with
allogeneic transplantation, including the use of submyeloabla-
tive approaches, relying on GVL effects [14,15,22,23] in patients
failing autografts. Encouragingly, a single previous case report
has demonstrated prolonged disease-free survival after BEAM
conditioning and allogeneic transplantation for HD [24].
Because of this data, we treated 10 patients who had all
failed autologous transplantation and other salvage regimens
with BEAM and an allograft, and we report our experiences.
PATIENTS AND METHODS
Patients
The study group consisted of consecutive patients with
advanced HD treated with allogeneic hematopoietic blood stem
cell or bone marrow transplant after failing an autograft at our
institution.
Other than conﬁrmed relapsed or refractory HD after au-
tograft, patient eligibility requirements included relapsed or
refractory HD where a second autograft was not feasible, in-
cluding persisting bone marrow inﬁltration, inability to collect
stem cells, associated major marrow disorders such as myelodys-
plasia, and early progression.
Pretransplantation investigations of end organ function
were performed. Satisfactory results of screening tests were
required, including the following: a cardiac ejection fraction of
at least 40%; absence of acute ischemia signiﬁcant arrhythmia
on electrocardiogram; respiratory function tests of at least 50%
predicted values (DLCO and FEV1), adequate renal function
(creatinine clearance of at least 60 mL/min), adequate hepatic
function (serum bilirubin no greater than 2.0 mg/dL), and ala-
nine aminotransferase within 3 times the upper normal limit
(unless due to the underlying condition). Absence of major
adverse reactions to the regimen drugs, absence of active infec-
tions, or absence of other contraindication to allogeneic trans-
plantation were also necessary.
An available and consenting compatible donor was required
with a 6 of 6 match on DNA-based typing of HLA antigens
(HLA-A, B, DR-B1) for matched unrelated donors (MUD); 5 of
6 or 6 of 6 match for siblings. Negative testing on standard
infectious disease markers was required.
Transplantation Practices
Myeloablative therapy consisted of standard BEAM [19]
(BCNU 300 mg/m2, Etoposide 800 mg/m2, Cytarabine 1600
mg/ m2, and Melphalan 140 mg/m2). Patients undergoing
MUD allografts received antithymocyte globulin of 15 mg/kg
on day -4 and day -3.
For GVHD prophylaxis, FK-506 and mini-methotrexate
were used. FK-506 intravenous infusion started on day -2 at 0.03
mg/kg over 24 hours, aiming at a therapeutic serum level of 10
to 20 ng/mL, changing to oral FK 506 when tolerated. Meth-
otrexate prophylaxis consisted of 10 mg/m2 on day 1 and 5
mg/m2 on days 3, 6, and 11.
All patients received intravenous pooled gamma-immuno-
globulin (Gammar-P I.V., Aventis Behring, King of Prussia, PA)
at 0.5 g/kg weekly for the ﬁrst 100 days posttransplantation.
Early weaning of graft versus host (GVH) prophylaxis was
planned, commencing at day 60.
Anti-infective therapy included cytomegalovirus (CMV)
prophylaxis (for CMV-negative patients: Acyclovir 500 mg/m2
every 8 hours intravenous (IV), changing to oral Valaciclovir
500 mg twice a day; for CMV-positive patients: Acyclovir 500
mg/m2 every 8 hours IV, changing to oral Valaciclovir 1000 mg
3 times a day until day 100), fungal prophylaxis with Itracon-
azole suspension (400 mg daily orally, or IV Amphoterecin, 0.2
mg/kg if patient is unable to swallow), and antibacterial prophy-
laxis with Norﬂoxacin 400 mg twice a day starting day -7.
Routine IV broad-spectrum antibiotics for febrile neutropenia
were administered, with additional antifungal therapy as indi-
cated. No speciﬁc prophylaxis for veno-occlusive disease was
administered.
The hemoglobin was maintained at a level 8 g/dL and the
platelet count at 20  109/L with ﬁltered, leukocyte-depleted,
and irradiated blood products, with CMV-negative patients re-
ceiving CMV-negative products.
Nutritional support included all patients receiving addi-
tional multivitamins and folic acid, with all MUD patients re-
ceiving elective total parenteral nutrition from day 1, whereas
this was used at the clinician’s judgment in other cases, as guided
by the caloric intake.
Definitions of Response and Outcome
Responses were classiﬁed using standard criteria. A CR was
deﬁned by complete disappearance of all measurable and evalu-
able disease, with no new lesions or disease-related symptoms. A
partial remission (PR) was deﬁned as a 50% decrease in the
sum of products or perpendicular diameters of all measurable
lesions. Donor chimerisms were performed using polymerase
chain reaction ampliﬁcation of micro satellite short tandem
repeat loci at approximately day 100 from a bone marrow
sample. To calculate the probabilities of disease-free survival
and overall survival, the Kaplan-Meier method was used [25].
This analysis was approved by the Loyola University Medical
Center Internal Review Board.
A preliminary analysis of prognostic factors was undertaken,
considering donor source, time of initial remission and remis-
sion duration after autograft, cell dose, length of hospital stay,
time of engraftment, pretransplantation performance status, and
serum lactate dehydrogenase.
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Posttransplantation, patients were followed at least weekly
clinically and with routine blood tests, underwent follow-up
computed tomography scans of the chest, abdomen, and pelvis,
and had bone marrow studies on day100. Further imaging was
performed at 6-month and 12-month intervals or as indicated
clinically or by other investigations.
DLIs for Relapsed Disease
Graduated infusions of donor lymphocytes starting at 5 
106 CD3 cells/kg for disease relapse were offered, without
further chemotherapy, for residual disease, or often additional
chemotherapy was offered for patients with clinically relapsing
disease.
RESULTS
A total of 10 patients have been treated to date. Patient
characteristics are summarized in Table 1. The mean age was 35
years (median, 37 years; range: 21 to 49 years). The mean time
from diagnosis to allogeneic transplantation was 73 months
(median, 55 months; range: 12 to 172 months), whereas the
average time from autograft to allograft was 49 months (median,
31 months; range: 5 to 143 months). Two patients had previ-
ously received tandem autografts.
Early features included extra-nodal disease in 2 cases, mean
short response to initial therapy of 9 months (median, 5 months;
range: 0 to 40 months), and failure to achieve CR in 5 cases. The
mean and median Southwestern Oncology Group performance
status [26] was 2 (range: 0 to 3).
Five patients received total body irradiation–containing au-
tografts, whereas 5 patients, who had received previous radio-
therapy, received chemotherapy-only autografts, 4 patients re-
ceived busulfan and cyclophosphamide, and 1 patient received
busulfan, VP-16, and cyclophosphamide.
At the time of transplantation, 1 patient was in CR, 5
patients were in PR, 3 patients were in relapse, and 1 patient had
primary refractory disease.
The median dose of peripheral blood stem cells was 7.3 
106 CD34  cells/kg (median, 7.2; range: 3.2 to 14.2), and for
bone marrow was 3.2  108 nucleated cells/kg (median, 3.6;
range: 1.9 to 4.0).
The mean time to relapse or progression after autograft was
21 months (range: 0 to 89). Six patients had received multiple
salvage chemotherapy regimens before autograft (2 to 5 courses).
Nine patients received treatments after relapsing after autograft,
4 with radiotherapy as well as chemotherapy courses, mean of
2.3 courses (range: 1 to 7 courses), prior to allogeneic transplan-
tation. All patients received BEAM conditioning at full dose.
As shown in Table 2, donors were as follows: 5 HLA-
matched siblings, 4 MUDs, and 1 mismatched sibling, 5 of 6
match with a mismatch at HLA-DR. Bone marrow was used for
the latter 5 cases, whereas peripheral blood stem cells were used
for the 5 matched sibling transplantations. Four patients were
CMV-positive, whereas all 6 CMV-negative patients received
Table 1. Patient Characteristics: from Diagnosis to Allograft
Patient
No. Age/Sex
Initial
Stage Histology
Initial
Prescription
Salvage
Chemotherapy
Longest
CR
(mo)
Regimen for
Autograft
Months to
Relapse
Post-
Autograft
Further
Chemotherapy
Post-Autograft
Status Pre-
Allograft
Months
Diagnosis
to
Allograft
SWOG
Performance
Status (at
Allograft)[26]
1 21 F II-A Nod Scl. Stanford V ICE (3), VP-
16, Cy
2 Mel 150
mg/m2
0 RT, ICE, Gem Refract./relapse 17 3
2 30 M III-B Nod Scl. MOPP Autograft 6 Bu/Cy 89 RT, DAB, and
IL-2, Gem
PR 134 0
3 38 M IV-B Nod Scl. ABVD Tandem
autograft
4 Mel/TBI/
VP16/Cy.
6 Gem (2) PR 28 2
4 49 M 1-Ae Nod Scl. MOPP/ABV ESHAP (4) 8 Mel and
BCV
4 Gem (2) PR 40 3
5 37 M III-A Nod Scl. MOPP/ABVD DHAP (2) 26 TBI/VP-16,
Cy
9 EPOCH (6),
Gem, MOPP
(3)
PR 97 2
6 38 M III-B Mixed Cell MOPP/ABVD Y L. Neck 45
Gy
6 Bu/Cy 35 RT, Vin, Gem,
MOPP,
EPOCH,
Gem
Vinblastine,
MOPP
Relapse 172 2
7 39 M III-Ae Nod Scl. Stanford V ICE (3)
MOPP, ICE,
Cy, VP-16
5 Cy/VP-16 7 Vin, Gem CR 22 1
8 39 M II-B Nod Scl. ABVD NA TBI/VP-16,
Cy
12 Vin 3 Relapse 28 2
9 29 F II-B Nod Scl. ABVD Autograft 4 TBI/VP-16,
Cy
11 RT, EPOCH,
Vin, Gem
PR 55 3
10 32 M IV-A LP/Mixed* MOPP/ABV DHAP (2) 40 TBI/VP-16,
Cy
36 Vin, Gem Relapse 132 0
*Lymphocyte predominant at diagnosis, mixed cellularity on ﬁrst relapse.
Stanford V indicates doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone; ABVD, Adriamycin, Bleo-
mycin, Vinblastine, and Dacarbazine; MOPP, Mustine, Vincristine, Prednisone, and Procarbazine; Cy, Cyclophosphamide; BCV, BCNU, Cy, VP16;
Mel, Melphalan; EPOCH, Etoposide, Prednisolone, Vincristine, Cyclophosphamide, and Adriamycin; ESHAP, Etoposide, etoposide, ara-C,
methylprednisolone, and cisplatin; ICE, Ifosfamide, Carboplatin, and Etoposide; DHAP, Dexamethasone, Ara; Gem, Gemcytobine; Vin, Vinoralbine;
RT, radiotherapy; F, female; M, male; NA, not applicable; Nod Scl, nodular sclerosing; Refract, refractory.
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CMV-negative donor cells. Five cases received donor cells that
were of major ABO incompatibility. Patients received granlo-
cyte–colony stimulating factor (Neupogen, Amgen Inc., Thou-
sand Oaks, CA) at approximately 5 g/kg/d starting on day12.
The mean inpatient stay from the time of transplantation
was 24 days (median, 23 days; range: 17 to 45 days).
Engraftment
All patients’ transplants engrafted promptly. The mean time
for an absolute neutrophil count (0.5  109/L) was 17 days
(median, 18 days; range: 14 to 21 days), whereas for unsupported
platelets (20  109/L) it was 31 days (median, 28 days; range:
14 to 69 days).
Response to BMT
All 10 evaluable patients responded to BEAM allogeneic
transplantation, with 8 obtaining CR (1 patient was in CR prior
to allotransplant) and 2 obtaining PR. Median follow-up is 12
months (range: 4 to 19 months). Nine remained alive (90%),
with 7 in CR (70%) (Figure 1 and Figure 2). One (10%) patient
died at 4 months after allograft due to refractory disease. Two
patients relapsed at 6 and 8 months posttransplantation (HD1
and 4), and are in stable relapse following further therapies,
including DLIs. One patient (HD1) received multiple infusions
with very minor chronic GVH and transient stabilization of
disease. She is receiving chemotherapy at this time. It is too early
to assess the response to DLI in the other patient (HD4).
Chimerism status was assessed as full donor hematopoiesis in all
8 assessable patients.
Nine of the 10 patients had FK-506 discontinued by day
100 (median, 90 days). Of the 3 patients who developed signif-
icant chronic graft-versus-host disease (GVHD), none have re-
lapsed. There was 1 case of minor transient signs of chronic
GVHD (cGVHD), which did not require treatment, where
subsequent relapse occurred. Of the other 5 assessable cases
without cGVHD, 2 have relapsed.
Toxicity
The conditioning regimen was fairly well tolerated. The
mean inpatient stay posttransplantation was 24 days (range: 16
to 45 days). All patients have survived beyond day 100. One
patient (HD9) had multiple problems, including a background
of high narcotic requirements, and developed severe mucositis
and veno-occlusive disease. She required respiratory support
with intubation and ventilation for 2 days. In this case, day 6
day 11 methotrexate was withheld, and grade IV gastrointes-
tinal and hepatic GVHD occurred. This subsequently re-
sponded to immunosuppresion including high-dose steroid,
which has since been fully withdrawn without problems. She has
mild chronic GVHD, not requiring therapy. One other patient
(HD6) had a prolonged inpatient stay, with problems of poor
oral intake, grade III acute gastrointestinal GVH, and aspergil-
lus pneumonia, which were treated successfully.
Four patients have developed chronic GVH. One case only
is currently being treated with systemic immunosuppresion,
after more recent progression (skin and liver involvement).
DISCUSSION
Reducing the transplant-related mortality enables alloge-
neic transplantation to be considered as a therapeutic option for
advanced HD. Since the initial reported series [6,7], gains have
been made in various areas [27] with improved results for allo-
geneic bone marrow transplantation over time [24]. This is
associated with patient selection, conditioning regimens, HLA
typing, early diagnosis, management of complications, including
GVH and infections, and prophylaxis. Many early HD allograft
recipients received total body irradiation–based conditioning
Table 2. Patient Characteristics from Allograft
Patient
Identifier Donor
Graft
Type
Acute
GVH
Best
Response
to Allograft
Donor
Chimerism cGVHD Relapse
Further
Therapy after
Relapse Response
Current
Status
HD1 Matched sibling PBSCT No PR 100% No Y Gemcytobine
(8), DLI
PR Alive
HD2 Matched sibling
5/6*
Marrow No CR 100% Mild N NA NA Alive
HD3 Matched sibling PBSCT No CR 100% Moderate/
Severe
N NA NA Alive
HD4 Matched sibling PBSCT No CR 96% Transient
mild
Y Vineralbine
(3), DLI
PR Alive
HD5 Matched sibling PBSCT No CR 99.6% No N NA NA Alive
HD6 MUD MUD
Marrow
Yes CR 100% Mild N NA NA Alive
HD7 MUD MUD
Marrow
No CR 100% No N NA NA Alive
HD8 Matched sibling PBSCT No PR NA No Y Vineralbine PR Dead
and Steroid
HD9 MUD MUD
Marrow
Yes CR 100% No N NA NA Alive
HD10 MUD MUD
Marrow
No CR Pending NA N NA NA Alive
PBSCT indicates peripheral blood stem cell transplantation; NA, not available; Y, yes; N, no.
*DR mismatch.
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[6,7]. Serological HLA typing was routinely performed at that
time, with its limitations. In our series, DNA-based typing of
HLA antigens was performed. All 4 patients undergoing MUD
transplantations are alive and in remission at this point, as is the
1 case of a 5 of 6 antigen-matched sibling donor. This indicates
that these are feasible options when matched sibling donors are
not available, even for these very high-risk patients who had
failed autografts.
Ongoing improvements in GVH prophylaxis, diagnosis,
and treatment continue [28]. Infections remain a major hazard
[29-31] although improvements include prophylaxis, early diag-
nosis, and imaging techniques. Other progress over time in-
cludes CMV prevention, detection, and treatment [30], antifun-
gal prophylaxis and treatment, use of high-efﬁciency particulate
air ﬁltering, detection of infections using polymerase chain re-
action and newer antigen-based techniques, and development of
new classes of anti-microbial therapy [30-32]. In previous reg-
istry data, which included BEAM conditioning, the early mor-
tality in HD allografts was signiﬁcant [13]. This is different than
our experience in this series, which uses these recent develop-
ments. Of interest, our patients had a relatively long average
time since autograft, although suboptimal performance status.
Our early results indicate that CR can be obtained, includ-
ing patients with long-standing recurrent disease and those with
persistent or refractory disease. In our series, BEAM condition-
ing is effective at obtaining disease remission in most patients
failing to reach CR prior to allogeneic transplantation. Early
weaning of immune suppression may assist the prompt devel-
opment of a graft-versus-tumor (GVL) effect.
Cases of disease relapse after transplantation (HD1, HD4,
and HD8) had more rapidly growing disease before transplan-
tation, with a limited response to initial chemotherapy (PR,
refractory, and PR, respectively) and short time to relapse after
autografting (refractory, 4 months, and 12 months, respec-
tively). Pretransplantation lactate dehydrogenase was not signif-
icant. It appears that there may be a subset of patients with
rapidly growing HD who will relapse despite allografting. Sup-
portive of a GVL effect, 2 patients have developed acute
GVHD, without evidence of relapse at early follow-up. Simi-
larly, the patient requiring systemic therapy for cGVHD is in
continuous remission at 18 months after transplantation. We
await further data and follow-up regarding the effectiveness of
DLI in patients relapsing after this regimen, and also the dura-
tion of remission in all cases, given that some were slow to
relapse after previous therapies, including autograft.
As has been seen at other centers [14,15,24], patients with
high-risk disease, such as primary refractory disease or chemo-
therapy-resistant relapse, may beneﬁt from up-front allogeneic
rather than autologous transplantation. Again, this relies on low
treatment-related mortality of allografts as seen here, unlike
those in early reports [9,18].
Other strategies for allogeneic transplantation in patients
relapsing after autografting include various types of sub-myeloa-
blative regimens [14,15,22,23]. It may be important to obtain
sustained disease control with chemotherapy, such as BEAM, to
reduce disease bulk and to control disease for 3 to 4 months
while GVL is established. The longer duration of immunosup-
presion in some non-myeloablative transplantation regimens
might hinder GVL effects. It is unclear whether a staged pro-
cedure with BEAM autografting followed promptly by sub-
myeloablative therapy [14] would provide additional safety. As
with our study, there are promising results with small numbers
of patients and short follow-up periods. Allogeneic transplanta-
tion for HD warrants larger studies with longitudinal follow-up.
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